000157801 001__ 157801
000157801 005__ 20250326091426.0
000157801 0247_ $$2doi$$a10.1002/mds.28424
000157801 0247_ $$2pmid$$apmid:33332647
000157801 0247_ $$2pmc$$apmc:PMC8247308
000157801 0247_ $$2ISSN$$a0885-3185
000157801 0247_ $$2ISSN$$a1531-8257
000157801 0247_ $$2altmetric$$aaltmetric:96221795
000157801 037__ $$aDZNE-2021-01258
000157801 041__ $$aEnglish
000157801 082__ $$a610
000157801 1001_ $$00000-0003-4711-0875$$aNissen, Sara Konstantin$$b0
000157801 245__ $$aSoluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
000157801 260__ $$aNew York, NY$$bWiley$$c2021
000157801 3367_ $$2DRIVER$$aarticle
000157801 3367_ $$2DataCite$$aOutput Types/Journal article
000157801 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742897179_24043
000157801 3367_ $$2BibTeX$$aARTICLE
000157801 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157801 3367_ $$00$$2EndNote$$aJournal Article
000157801 520__ $$aParkinson's disease (PD) is a neurodegenerative disorder with a significant immune component, as demonstrated by changes in immune biomarkers in patients' biofluids. However, which specific cells are responsible for those changes is unclear because most immune biomarkers can be produced by various cell types.The aim of this study was to explore monocyte involvement in PD.We investigated the monocyte-specific biomarker sCD163, the soluble form of the receptor CD163, in cerebrospinal fluid (CSF) and serum in two experiments, and compared it with other biomarkers and clinical data. Potential connections between CD163 and alpha-synuclein were studied in vitro.CSF-sCD163 increased in late-stage PD and correlated with the PD biomarkers alpha-synuclein, Tau, and phosphorylated Tau, whereas it inversely correlated with the patients' cognitive scores, supporting monocyte involvement in neurodegeneration and cognition in PD. Serum-sCD163 increased only in female patients, suggesting a sex-distinctive monocyte response. CSF-sCD163 also correlated with molecules associated with adaptive and innate immune system activation and with immune cell recruitment to the brain. Serum-sCD163 correlated with proinflammatory cytokines and acute-phase proteins, suggesting a relation to chronic systemic inflammation. Our in vitro study showed that alpha-synuclein activates macrophages and induces shedding of sCD163, which in turn enhances alpha-synuclein uptake by myeloid cells, potentially participating in its clearance.Our data present sCD163 as a potential cognition-related biomarker in PD and suggest a role for monocytes in both peripheral and brain immune responses. This may be directly related to alpha-synuclein's proinflammatory capacity but could also have consequences for alpha-synuclein processing. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000157801 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000157801 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000157801 650_7 $$2Other$$aalpha-synuclein
000157801 650_7 $$2Other$$abiomarkers
000157801 650_7 $$2Other$$acognition
000157801 650_7 $$2Other$$amonocytes
000157801 650_7 $$2Other$$asCD163
000157801 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000157801 650_7 $$2NLM Chemicals$$aAntigens, CD
000157801 650_7 $$2NLM Chemicals$$aAntigens, Differentiation, Myelomonocytic
000157801 650_7 $$2NLM Chemicals$$aBiomarkers
000157801 650_7 $$2NLM Chemicals$$aCD163 antigen
000157801 650_7 $$2NLM Chemicals$$aPeptide Fragments
000157801 650_7 $$2NLM Chemicals$$aReceptors, Cell Surface
000157801 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000157801 650_2 $$2MeSH$$aAmyloid beta-Peptides
000157801 650_2 $$2MeSH$$aAntigens, CD
000157801 650_2 $$2MeSH$$aAntigens, Differentiation, Myelomonocytic
000157801 650_2 $$2MeSH$$aBiomarkers
000157801 650_2 $$2MeSH$$aCognition
000157801 650_2 $$2MeSH$$aFemale
000157801 650_2 $$2MeSH$$aHumans
000157801 650_2 $$2MeSH$$aMonocytes
000157801 650_2 $$2MeSH$$aParkinson Disease: complications
000157801 650_2 $$2MeSH$$aPeptide Fragments
000157801 650_2 $$2MeSH$$aReceptors, Cell Surface
000157801 650_2 $$2MeSH$$aalpha-Synuclein
000157801 7001_ $$aFerreira, Sara Almeida$$b1
000157801 7001_ $$aNielsen, Marlene Christina$$b2
000157801 7001_ $$0P:(DE-2719)9000366$$aSchulte, Claudia$$b3$$udzne
000157801 7001_ $$aShrivastava, Kalpana$$b4
000157801 7001_ $$aHennig, Dorle$$b5
000157801 7001_ $$aEtzerodt, Anders$$b6
000157801 7001_ $$aGraversen, Jonas Heilskov$$b7
000157801 7001_ $$0P:(DE-2719)2000059$$aBerg, Daniela$$b8$$udzne
000157801 7001_ $$0P:(DE-2719)2810915$$aMaetzler, Walter$$b9$$udzne
000157801 7001_ $$aPanhelainen, Anne$$b10
000157801 7001_ $$aMøller, Holger Jon$$b11
000157801 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b12$$udzne
000157801 7001_ $$00000-0003-0970-578X$$aRomero-Ramos, Marina$$b13$$eCorresponding author
000157801 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28424$$gVol. 36, no. 4, p. 963 - 976$$n4$$p963 - 976$$tMovement disorders$$v36$$x1531-8257$$y2021
000157801 8564_ $$uhttps://pub.dzne.de/record/157801/files/DZNE-2021-01258.pdf$$yOpenAccess
000157801 8564_ $$uhttps://pub.dzne.de/record/157801/files/DZNE-2021-01258.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000157801 909CO $$ooai:pub.dzne.de:157801$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000157801 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000366$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000157801 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000059$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000157801 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810915$$aExternal Institute$$b9$$kExtern
000157801 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000157801 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000157801 9141_ $$y2021
000157801 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000157801 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000157801 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000157801 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000157801 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000157801 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000157801 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000157801 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000157801 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000157801 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000157801 9201_ $$0I:(DE-2719)5000055$$kAG Berg$$lParkinson's Disease Genetics$$x1
000157801 980__ $$ajournal
000157801 980__ $$aVDB
000157801 980__ $$aUNRESTRICTED
000157801 980__ $$aI:(DE-2719)1210000
000157801 980__ $$aI:(DE-2719)5000055
000157801 9801_ $$aFullTexts